June 24, 2025
AOI Biosciences Inc.
AOI Biosciences Inc. (Headquarters: Ibaraki, Osaka, Japan; CEO: Shinichi Sueta; hereinafter referred to as “AOI Bio.”), has signed a joint research agreement with Sumitomo Corporation (Head office: Chiyoda-ku, Tokyo, Japan; Representative Director, President and CEO: Shingo Ueno; hereinafter “Sumitomo Corporation”) and PT Medika Loka Manajemen (Head office：Jakarta, Indonesia; President Director: Yulisar Khiat, hereinafter “Hermina”), which operates Hermina Hospitals. This agreement aims to explore the relationship between β2GPI Neoself antibodies and recurrent pregnancy loss in preparation for offering the “β2GPI Neoself Antibody Test” in Indonesia.
The joint research will involve measuring β2GPI Neoself antibody titers in 100 recurrent pregnancy loss patients aged 18–45 who visit Hermina hospitals, to confirm the antibody’s positivity rate. The study aims to clarify the utility of testing for β2GPI Neoself antibodies in addressing recurrent pregnancy loss in Indonesia, paving the way for the test’s introduction in the country.
Signing Ceremony at Hermina Hospital
From left：Sarah Safira Umarghanies (Hermina), Sri Mulyani (Hermina), Shigeru Ueda (Sumitomo), Shinichi Sueta (AOI Bio.), Yulisar Khiat (Hermina), Yasunori Ishibashi (Sumitomo), Moh Heri Kurniawan (Hermina), Yoarva (Hermina)
About the β2GPI Neoself Antibody Test
This innovative blood test identifies neoself antibodies, which are implicated for miscarriages and thrombosis, accounting for approximately 20% of recurrent pregnancy loss cases. Recent studies have also reported a connection between these antibodies and infertility. Clinical research has demonstrated that, for patients with positive test results, implementing appropriate medical intervention led to a live birth rate approximately 1.7 times higher in recurrent pregnancy loss cases and a pregnancy rate more than twice as high in infertility cases. AOI Bio. holds exclusive rights, granted by Osaka University, to conduct this test. The test is also recognized as Advanced Medical Care1 within Japan.
（1）Advanced medical care refers to treatments and technologies not yet covered by Japan’s national health insurance, but still recognized by the Ministry of Health, Labour and Welfare (MHLW). These treatments can be provided to patients simultaneously with insurance-covered medical services, under specific standards for participating medical facilities and methods established by the government.
■ About AOI Biosciences Inc.
Company Name：AOI Biosciences Inc.（https://www.aoibio.com/en）
Business Overview：AOI Biosciences integrates bioinformatics with proprietary biotechnology, focusing on infectious diseases and autoimmune disorders. The company engages in diagnostic testing, drug discovery, and drug discovery support businesses, continuously contributing to the health and well-being of people worldwide.
Date of Incorporation：November 2019
■ About Sumitomo Corporation
Company Name：Sumitomo Corporation（https://www.sumitomocorp.com/en/jp）
Sumitomo Corporation (TYO: 8053) is an integrated trading and business investment company with a strong global network comprising 129 offices in 66 countries and regions. The Sumitomo Corporation Group consists of approximately 900 companies and 80,000 employees on a consolidated basis. The Group’s business activities are spread across the following nine groups: Steel, Automotive, Transportation & Construction Systems, Diverse Urban Development, Media & Digital, Lifestyle Business, Mineral Resources, Chemicals Solutions and Energy Transformation Business. Sumitomo Corporation is committed to creating greater value for society under the corporate message of “Enriching lives and the world,” based on Sumitomo’s business philosophy passed down for over 400 years.
■ About Hermina
Company Name：Hermina Hospital Group (https://www.herminahospitals.com/)
PT Medikaloka Hermina Tbk (Hermina Hospital Group), listed on the Indonesia Stock Exchange (IDX: HEAL), stands as one of Indonesia’s largest private healthcare providers, operating 52 general hospitals with over 6,600 beds across the nation. Annually serving more than six million outpatients and over 375 thousand inpatients, the group leverages a robust network of over 4,600 doctors and specialists. Founded in 1967 as a small maternity clinic in East Jakarta, Hermina has evolved from its core focus on women’s and children’s health into a comprehensive healthcare provider offering advanced tertiary services including cardiology, oncology, and neurology, while maintaining a dual-payer system supporting both private patients and Indonesia’s national health insurance (BPJS).
■ For inquiries about this press release, contact
e-mail：hello@aoibio.com
